| Literature DB >> 31901719 |
Abstract
Therapies for myasthenia gravis (MG) include symptomatic and immunosuppressive/immunomodulatory treatment. Options for immunosuppression include corticosteroids, azathioprine, mycophenolate mofetil, cyclosporine, tacrolimus, methotrexate, rituximab, cyclophosphamide, eculizumab, intravenous immunoglobulin, subcutaneous immunoglobulin, plasmapheresis, and thymectomy. The practical aspects of long-term immunosuppressive therapy in MG are critically reviewed in this article. Application of one or more of these specific therapies is guided based on known efficacy, adverse effect profile, particular disease subtype and severity, and patient co-morbidities.Entities:
Keywords: Corticosteroid; Immunosuppression; Intravenous immunoglobulin; Myasthenia gravis; Non-steroid immunosuppressive agent; Plasmapheresis; Thymectomy
Mesh:
Substances:
Year: 2019 PMID: 31901719 DOI: 10.1016/j.jns.2019.116648
Source DB: PubMed Journal: J Neurol Sci ISSN: 0022-510X Impact factor: 3.181